Multiple Myeloma Diagnosis Market Size, Share, Growth, and Industry Analysis, By Type (Routine IVD Testing, Clinical Trials), By Application (Pharmaceutical Company, Medical Labs, Academic & Medical Schools, Others), Regional Insights and Forecast from 2026 to 2035

•   
•   
  

  Download Free Sample to learn more about this report

    

MULTIPLE MYELOMA DIAGNOSIS MARKET OVERVIEW

The global Multiple Myeloma Diagnosis Market size estimated at USD 35.75 billion in 2026 and is projected to reach USD 106.35 billion by 2035, growing at a CAGR of 12.88% from 2026 to 2035.

The Multiple Myeloma Diagnosis Market is expanding due to rising hematologic cancer screening rates, increasing laboratory automation, and wider adoption of molecular diagnostic technologies. More than 187,000 new multiple myeloma cases were recorded globally in 2024, while over 114,000 deaths were associated with plasma cell malignancies. Bone marrow biopsy testing accounts for nearly 41% of diagnostic procedures, while serum protein electrophoresis contributes close to 29% of total testing demand. Hospital laboratories perform over 58% of diagnostic workflows globally. Flow cytometry utilization increased by 33% across oncology laboratories during 2024. Diagnostic sensitivity for next-generation sequencing tests reached 94% in advanced disease detection applications across specialized oncology centers.

The United States represents the largest contributor to the Multiple Myeloma Diagnosis Market due to strong oncology infrastructure and high screening adoption. More than 36,000 new multiple myeloma cases were diagnosed in the U.S. during 2024, with adults above 65 years accounting for nearly 61% of total cases. Clinical laboratories in the country processed over 8.4 million hematology diagnostic tests linked to plasma cell disorders during 2024. Immunofixation electrophoresis utilization increased by 27% across cancer centers, while advanced genomic testing adoption crossed 39% in tertiary hospitals. More than 72% of U.S. oncology hospitals integrated automated diagnostic analyzers for early-stage myeloma identification and disease progression monitoring.

KEY FINDINGS

LATEST TRENDS

The Multiple Myeloma Diagnosis Market is witnessing substantial transformation through integration of molecular diagnostics, digital pathology, and artificial intelligence-driven interpretation systems. More than 63% of oncology hospitals introduced automated hematology analyzers during 2024 to improve diagnostic precision and reduce turnaround time. Next-generation sequencing adoption increased by 34% in cancer diagnostic centers, while fluorescence in situ hybridization testing utilization expanded by 28% globally. Minimal residual disease testing penetration crossed 37% across specialized oncology clinics due to rising emphasis on early relapse detection.

Liquid biopsy testing is emerging as a significant trend, with adoption increasing by 26% in hematologic malignancy monitoring applications. Multiparameter flow cytometry continues to dominate laboratory-based diagnosis, accounting for nearly 44% of advanced diagnostic workflows globally. Automated immunoassay systems reduced laboratory processing time by 31%, improving clinical efficiency across tertiary care facilities. Digital pathology integration in oncology laboratories increased by 22%, while cloud-based laboratory information systems expanded by 35% in diagnostic centers.

MARKET DYNAMICS

Driver

Rising demand for early cancer detection and precision diagnostics.

The increasing global prevalence of hematologic malignancies continues to accelerate demand for advanced multiple myeloma diagnostic technologies. More than 187,000 new cases were reported worldwide during 2024, while nearly 61% of diagnosed patients were aged above 65 years. Early-stage detection improved survival outcomes by 47%, encouraging hospitals and oncology laboratories to expand screening programs. Flow cytometry adoption increased by 33% globally because of its ability to identify abnormal plasma cells with high sensitivity.

Restraint

High diagnostic equipment costs and reimbursement limitations.

Advanced molecular diagnostic systems and genomic analyzers require substantial capital investment, limiting adoption among smaller healthcare facilities. More than 42% of independent diagnostic laboratories reported delayed procurement of automated testing systems due to high equipment costs. Reimbursement coverage limitations affected approximately 37% of specialized myeloma diagnostic procedures globally during 2024. Maintenance costs for next-generation sequencing platforms increased by 18%, while skilled pathology workforce shortages reduced operational efficiency by 29% in emerging healthcare markets.

Expansion of personalized medicine and genomic profiling technologies

Opportunity

The increasing adoption of precision oncology creates substantial growth opportunities for advanced multiple myeloma diagnostic solutions. More than 41% of hematologic cancer clinical trials incorporated biomarker-based patient selection during 2024. Genomic sequencing utilization expanded by 34%, while minimal residual disease testing adoption increased by 27% globally.

Pharmaceutical companies invested heavily in companion diagnostic collaborations, supporting targeted therapy development and personalized treatment strategies.

Complexity of disease diagnosis and variability in testing standards

Challenge

Multiple myeloma diagnosis involves numerous laboratory procedures including serum electrophoresis, bone marrow biopsy, imaging, and molecular profiling, creating workflow complexity across healthcare systems. More than 32% of laboratories reported inconsistencies in biomarker interpretation standards during 2024.

Variability in sample preparation procedures affected testing accuracy by nearly 18% across decentralized laboratories. Diagnostic turnaround time exceeded 7 days in approximately 36% of regional hospitals due to limited automation and specialist shortages.

•   
•   
  

  Download Free Sample to learn more about this report

    

MULTIPLE MYELOMA DIAGNOSIS MARKET SEGMENTATION

By Type

• Routine IVD Testing: Routine IVD testing represents the largest segment within the Multiple Myeloma Diagnosis Market, accounting for nearly 67% of global testing demand during 2024. Serum protein electrophoresis remains one of the most widely used procedures, contributing approximately 34% of routine hematology testing workflows. Immunofixation testing utilization increased by 27% globally due to rising requirements for monoclonal protein detection. Hospital laboratories perform over 58% of routine multiple myeloma diagnostic procedures, while automated analyzers reduced laboratory processing time by 31%.

• Clinical Trials: Clinical trial diagnostics account for nearly 33% of the Multiple Myeloma Diagnosis Market due to increasing precision oncology research activities. More than 41% of ongoing hematologic cancer clinical trials incorporated genomic profiling during 2024. Minimal residual disease testing adoption within clinical trials increased by 29%, while biomarker-driven patient enrollment procedures expanded by 24%. Pharmaceutical research collaborations with diagnostic companies increased by 21%, accelerating development of companion diagnostic assays.

By Application

• Pharmaceutical Company: Pharmaceutical companies account for approximately 38% of application demand within the Multiple Myeloma Diagnosis Market due to increasing targeted therapy development. More than 46% of pharmaceutical oncology programs incorporated companion diagnostics during 2024. Biomarker screening utilization increased by 28% in hematologic cancer drug development activities, while genomic sequencing adoption expanded by 34%. Clinical trial enrollment supported by molecular diagnostic testing rose by 22% globally.

• Medical Labs: Medical laboratories contribute nearly 31% share of the Multiple Myeloma Diagnosis Market because of rising hematology testing volumes and increasing automation adoption. More than 8.4 million plasma cell disorder diagnostic procedures were processed globally during 2024 across independent and hospital-affiliated laboratories. Automated immunoassay systems reduced diagnostic turnaround time by 26%, while flow cytometry integration increased by 33%. Serum free light chain testing utilization exceeded 52% across specialized hematology laboratories.

• Academic & Medical Schools: Academic and medical schools represent approximately 19% share of the Multiple Myeloma Diagnosis Market due to increasing oncology research activities and educational investments. More than 3,800 hematologic cancer studies were conducted globally during 2024, while research funding for plasma cell disorder diagnostics increased by 23%. Genomic sequencing utilization within academic institutes expanded by 31%, supporting biomarker discovery and precision medicine development. Approximately 44% of oncology training hospitals integrated advanced flow cytometry platforms into laboratory education programs.

• Others: Other applications including specialty oncology clinics, independent diagnostic centers, and community healthcare providers account for nearly 12% of market demand. Specialty clinics increased adoption of portable diagnostic analyzers by 17% during 2024 to improve accessibility in decentralized healthcare environments. Telepathology implementation expanded by 19%, enabling remote diagnostic consultation for hematologic malignancies. Independent cancer centers contributed approximately 26% of outpatient diagnostic procedures globally.

•   
•   
  Download Free Sample to learn more about this report

    

MULTIPLE MYELOMA DIAGNOSIS MARKET REGIONAL INSIGHTS

• North America

North America accounts for 33% of the global multiple myeloma diagnosis market, supported by advanced healthcare infrastructure, increasing availability of diagnostic technologies, and strong adoption of specialized oncology testing methods. The United States represents the major contributor due to the presence of advanced cancer care centers, improved access to molecular diagnostics, and rising focus on early disease detection. Canada also contributes through expanding hematology services and healthcare investments. Growing adoption of blood-based testing, imaging techniques, bone marrow analysis, and personalized diagnostic approaches is improving multiple myeloma identification. Increasing awareness among healthcare providers and patients is further strengthening demand for advanced diagnostic solutions across the region.

• Europe

Europe represents 28% of the global multiple myeloma diagnosis market, driven by established healthcare systems, increasing cancer screening initiatives, and growing adoption of advanced diagnostic procedures. Countries such as Germany, France, the United Kingdom, Italy, and Spain are major contributors due to their strong oncology research capabilities and access to specialized medical facilities. The region is witnessing higher use of immunological testing, imaging technologies, genetic analysis, and laboratory-based diagnostic methods for detecting multiple myeloma. Rising investments in cancer research, improved healthcare accessibility, and increasing emphasis on early diagnosis are supporting market development. Collaborative healthcare programs and advancements in precision medicine are further enhancing diagnostic capabilities across Europe.

• Asia-Pacific

Asia-Pacific holds 24% of the global multiple myeloma diagnosis market, supported by improving healthcare infrastructure, rising cancer awareness, and increasing adoption of advanced diagnostic technologies. Countries including China, Japan, India, South Korea, and Australia are key contributors due to expanding oncology facilities and growing demand for effective cancer detection methods. Japan and South Korea benefit from advanced medical systems, while China and India are witnessing increased investment in diagnostic laboratories and healthcare modernization. Growing patient populations, improved access to specialized testing, and rising adoption of biomarker-based diagnostics are driving regional demand. Government healthcare initiatives and increasing availability of oncology services are further supporting market expansion.

• Middle East & Africa

Middle East & Africa contributes 8% of the global multiple myeloma diagnosis market, supported by improving healthcare facilities, increasing awareness of blood cancers, and expanding access to specialized diagnostic services. Countries such as Saudi Arabia, the United Arab Emirates, and South Africa are important contributors due to investments in oncology centers, laboratory infrastructure, and advanced medical technologies. The region is witnessing increased adoption of diagnostic imaging, blood testing, and pathology services for cancer detection. Growing healthcare modernization programs and efforts to improve early disease identification are creating new opportunities for diagnostic providers. Expansion of specialized cancer treatment facilities is also supporting the development of regional diagnostic capabilities.

• Rest of World

Rest of World accounts for 7% of the global multiple myeloma diagnosis market, with Latin America representing a significant portion of regional demand. Countries such as Brazil, Mexico, Argentina, and Colombia contribute through improving healthcare access, expanding diagnostic laboratories, and increasing focus on cancer management. Brazil and Mexico are key markets due to their larger patient populations and growing investment in healthcare infrastructure. Rising awareness about hematological cancers, improved availability of diagnostic tests, and increasing collaboration between healthcare institutions are supporting market growth. Development of modern medical facilities and wider access to oncology services are creating additional opportunities for multiple myeloma diagnosis solutions across emerging markets.

KEY INDUSTRY PLAYERS

The global Multiple Myeloma Diagnosis Market consists of leading diagnostic companies, laboratory technology providers, and healthcare organizations focused on improving early detection, disease classification, monitoring, and treatment assessment. Companies such as Roche Diagnostics, Abbott Laboratories, and Siemens Healthineers are strengthening their market presence through advanced blood tests, immunoassays, imaging systems, and laboratory diagnostic technologies used in multiple myeloma evaluation. Thermo Fisher Scientific, Bio-Rad Laboratories, and Danaher are developing diagnostic platforms that support protein analysis, immunofixation, molecular testing, and laboratory workflows.

Diagnostic technology providers including DiaSorin, Agilent Technologies, and QIAGEN are focusing on specialized testing solutions for identifying abnormal plasma cells, monoclonal proteins, genetic changes, and disease progression. Companies are investing in automated laboratory systems, flow cytometry, molecular diagnostics, digital pathology, advanced imaging, and biomarker-based testing to improve diagnostic accuracy and monitoring efficiency. The competitive landscape is driven by increasing awareness of multiple myeloma, growing demand for earlier diagnosis, rising adoption of advanced laboratory testing, improved biomarker detection, and the increasing use of precision diagnostic technologies across hospitals, diagnostic laboratories, and specialized cancer centers.

LIST OF TOP MULTIPLE MYELOMA DIAGNOSIS COMPANIES

• Danaher Corporation
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.
• bioMérieux S.A.
• Parexel
• SkylineDx
• Sysmex Corporation
• Abbott Laboratories
• Bioclinica
• DiaSorin S.p.A.
• Siemens Healthcare
• Thermo Fisher Scientific Inc
• Sebia
• Ortho Clinical Diagnostics

List Of Top 2 Companies Market Share

• Danaher Corporation held approximately 16% share in the global multiple myeloma diagnosis industry during 2024 due to strong molecular diagnostics and flow cytometry product portfolios.

• Thermo Fisher Scientific Inc accounted for nearly 13% market share supported by extensive genomic sequencing platforms and oncology diagnostic reagent distribution networks.

INVESTMENT ANALYSIS AND OPPORTUNITIES

Investment activity in the Multiple Myeloma Diagnosis Market increased substantially during 2024 due to rising demand for precision oncology and automated laboratory systems. Global oncology diagnostic infrastructure investments expanded by 27%, while genomic sequencing laboratory installations increased by 24%. More than 41% of hematologic oncology clinical trials incorporated biomarker-based testing procedures, encouraging pharmaceutical companies to invest in companion diagnostic development partnerships. Venture capital funding in molecular pathology startups increased by 19%, supporting innovation in liquid biopsy and AI-assisted diagnostic technologies.

Hospital modernization programs improved adoption of digital pathology platforms by 22%, while laboratory automation investments expanded by 31% across tertiary healthcare facilities. Emerging economies increased oncology screening budgets by 18%, creating opportunities for diagnostic manufacturers to expand regional operations. Telepathology integration grew by 16%, improving accessibility to specialized hematology diagnostics in remote areas.

NEW PRODUCT DEVELOPMENT

New product development in the Multiple Myeloma Diagnosis Market is focused on molecular diagnostics, AI-assisted pathology systems, and high-sensitivity testing platforms. More than 24% of newly launched oncology diagnostic products during 2024 included genomic profiling capabilities. Automated flow cytometry analyzers improved plasma cell detection sensitivity by 32%, while next-generation sequencing platforms reduced diagnostic processing time by 26%.

Liquid biopsy innovation expanded significantly, with adoption of circulating tumor DNA testing increasing by 21% in hematologic malignancy monitoring applications. Artificial intelligence-powered pathology software improved interpretation accuracy by 29% across pilot oncology laboratories. Diagnostic reagent manufacturers introduced high-throughput immunoassay kits capable of processing over 1,200 samples daily in centralized laboratories.

FIVE RECENT DEVELOPMENTS (2023-2025)

• In 2025, Danaher Corporation expanded automated flow cytometry deployment capacity by 23% across oncology laboratories to improve plasma cell disorder testing efficiency.
• In 2024, Thermo Fisher Scientific Inc launched advanced genomic sequencing panels capable of increasing mutation detection sensitivity by 31% for hematologic malignancies.
• In 2024, Sysmex Corporation introduced upgraded hematology analyzers with 28% faster sample processing performance for oncology diagnostic laboratories.
• In 2023, Sebia improved immunofixation electrophoresis testing accuracy by 19% through development of enhanced protein separation technologies.
• In 2025, Abbott Laboratories expanded AI-integrated pathology software deployment by 22% to strengthen hematologic cancer screening efficiency across hospital laboratories.

MULTIPLE MYELOMA DIAGNOSIS MARKET REPORT COVERAGE

The Multiple Myeloma Diagnosis Market report covers diagnostic technologies, testing procedures, application areas, competitive landscape, and regional performance across major healthcare economies. The report analyzes more than 14 leading diagnostic manufacturers and evaluates utilization trends for flow cytometry, serum electrophoresis, immunoassays, genomic sequencing, and bone marrow pathology testing. Over 65% of report coverage focuses on advanced molecular diagnostic technologies and automation trends shaping oncology laboratory modernization.

The study evaluates diagnostic adoption patterns across pharmaceutical companies, medical laboratories, academic institutes, and specialty oncology centers. Regional analysis covers North America, Europe, Asia-Pacific, and Middle East & Africa, representing over 95% of global hematology diagnostic activity. More than 120 quantitative data points related to testing penetration, screening rates, hospital automation, and biomarker adoption are included within the report scope.